Prostate cancer ranges from localized, low risk to metastatic, morbid disease. Although radiation therapy (RT) is commonly incorporated in the treatment of early disease or for palliation of symptomatic lesions, its role in extending survival in metastatic disease is less well-established. Here, we review the available evidence surrounding localized RT in the presence of oligometastatic disease and metastasis-directed therapy in both hormone-sensitive and hormone-resistant prostate cancer. We further outline potential future incorporation of RT as an immune-sensitizing therapy and the importance of highly sensitive imaging modalities in considering RT in metastatic disease.
|Original language||English (US)|
|Number of pages||9|
|Journal||International Journal of Radiation Oncology Biology Physics|
|State||Published - Nov 15 2022|
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
- Cancer Research